Barclays analyst Stephanie Davis maintained a Buy rating on GoodRx Holdings (GDRX – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $6.93.
Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Health Catalyst, and Laboratory. According to TipRanks, Davis has an average return of -7.1% and a 39.67% success rate on recommended stocks.
GoodRx Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $8.88, which is a 28.14% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $10.00 price target.
The company has a one-year high of $9.37 and a one-year low of $4.14. Currently, GoodRx Holdings has an average volume of 1.4M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings (GDRX) Company Description:
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
Read More on GDRX:
- Notable companies reporting before tomorrow’s open
- Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky LLP Before June 21, 2024 to Discuss Your Rights – GDRX
- Yum! downgraded, Cava upgraded: Wall Street’s top analyst calls
- GoodRx upgraded to Overweight from Sector Weight at KeyBanc
- GoodRx files to sell 99.98M shares of Class A common stock for holders
